Telazorlimab

• CAT Number: I042119
• CAS Number: 2126777-87-3
• Purity: ≥95%

Telazorlimab (Cat No.: I042119) is a human monoclonal antibody that targets CD40, a co-stimulatory receptor expressed on antigen-presenting cells and involved in immune activation. By modulating the CD40-CD40L signaling pathway, Telazorlimab can either enhance or suppress immune responses, depending on the therapeutic context. It is being investigated for autoimmune diseases, transplant rejection, and cancer immunotherapy. Telazorlimab holds promise for precisely regulating immune responses, making it a valuable tool in research and development of treatments that require controlled immune modulation.

Reference

[1]. Guttman-Yassky E, et, al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019 Aug;144(2):482-493.e7.
[Content Brief]